Trent Kamke Sells 1,044 Shares of LeMaitre Vascular (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) insider Trent Kamke sold 1,044 shares of the firm’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $110.29, for a total value of $115,142.76. Following the completion of the sale, the insider directly owned 6,677 shares of the company’s stock, valued at $736,406.33. The trade was a 13.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

LeMaitre Vascular Trading Up 0.4%

LeMaitre Vascular stock opened at $107.85 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 10.95 and a current ratio of 12.89. The stock has a market cap of $2.46 billion, a PE ratio of 42.97, a price-to-earnings-growth ratio of 2.01 and a beta of 0.66. The stock has a 50-day moving average of $87.95 and a two-hundred day moving average of $88.48. LeMaitre Vascular, Inc. has a one year low of $71.42 and a one year high of $115.33.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.01. The firm had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The company’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th will be paid a $0.25 dividend. The ex-dividend date is Thursday, March 12th. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio (DPR) is 31.87%.

More LeMaitre Vascular News

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Company announced a dividend increase (quarterly dividend raised to $0.25) and a share buyback program, a catalyst that lifted investor sentiment and helped drive the rally. Read More.
• Positive Sentiment: Analyst support has improved — at least one firm raised its price target to $118 and other shop upgrades/positive notes add buy-side conviction around the stock. Read More.
• Positive Sentiment: Technical picture is constructive after a recent “golden cross” (50‑day MA crossing above 200‑day), which can attract momentum and technical buying. Read More.
• Neutral Sentiment: Recent quarterly results beat consensus (EPS and revenue) and management set FY2026 guidance (EPS 2.81–3.01), which provides useful context for longer-term holders but is already baked into current momentum. Read More.
• Negative Sentiment: Significant insider selling was reported recently — including CEO George W. LeMaitre (150,000 shares on Feb 26 and 55,930 on Mar 2), a director sale and an officer sale — totaling roughly ~215k shares disclosed across filings; this could create short‑term selling pressure or raise governance/insider‑confidence questions for some investors. Read More.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in LMAT. Parkside Financial Bank & Trust grew its holdings in shares of LeMaitre Vascular by 1,913.3% during the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 287 shares in the last quarter. Cornerstone Planning Group LLC boosted its position in LeMaitre Vascular by 534.0% during the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 283 shares during the last quarter. MAI Capital Management purchased a new stake in LeMaitre Vascular during the 3rd quarter valued at about $38,000. First Horizon Corp acquired a new stake in LeMaitre Vascular in the 3rd quarter valued at about $39,000. Finally, Geneos Wealth Management Inc. raised its holdings in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 398 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Barrington Research raised their price target on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Cantor Fitzgerald reissued a “neutral” rating and set a $95.00 target price on shares of LeMaitre Vascular in a report on Monday, November 10th. Wells Fargo & Company upped their price target on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a report on Thursday, February 26th. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Finally, Roth Mkm reissued a “buy” rating and issued a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Three analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $105.80.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.